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Results. Echocardiographic parameters, 6 min walk test distance did not 
differ significantly between the groups (p=0,027). After 12 weeks of treatment 
with meldonium the incidence of exertion-related symptoms, including chest pain, 
dyspnoea, fatigue were significantly lower in the 1st  in comparison with the 2nd 
groups (p=0,05). The distance of the 6 min walk test in 31 % pts have been increased 
in the 1st group by 26,47 % (р<0.01); in the 2nd group in 20 % pts – by 9,47 % 
(р<0,01). 6 min walk test correlated to NYHA functional class (r=0,25; р<0,05). 
After 12 weeks of treatment with meldonium the 1st group had significantly less 
stenotic progression, than the 2nd group (average decrease in AVA; 0,14 sm2 versus 
0.19 sm2, respectively (p<0,05)).  
Conclusion. Meldonium is effective and safe for the elderly pts with CHF and 
preserved ejection fraction and AS. Meldonium reduces progression of CHF and AS. 
Its administration may provide benefits for the reduction of hospitalizations and 
mortality in this category patients.
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Background. According to ESC guidelines 2016 for the diagnosis and treatment 
of heart failure, a patient who has never exhibited the typical symptoms and/or signs 
of heart failure (HF) and with a reduced left ventrical (LV) ejection fraction (EF) is 
described as having asymptomatic LV systolic dysfunction (ALVD). The absence of 
clinical signs and symptoms of HF may reflect the delay in the process of diagnosis 
and therapy.
IHD is the most common comorbidity and the leading cause of hospitalization 
in patients with COPD. Indeed, numerous epidemiological studies have shown 
that COPD, independent of cigarette smoking and aging, doubles the risk of CVD 
hospitalization and death. To date, the mutual burdens of IHD and COPD have been 
proven. Left ventricular dysfunction in IHD aggravates the effects of COPD through 
impairment of pulmonary hemodynamics. The basis for unfavorable interaction of 
IHD and COPD is systolic and diastolic dysfunction of the left ventricle due to its 
hypertrophy, increased aortic stiffness, hypoxia effect, right ventrical dysfunction.
The aim of this study was to estimate of asymptomatic LVD in patients with 
IHD and COPD while in a stable condition.
Materials and methods: 45 patients were included in this study (male – 32 
(71,1 %), female – 13 (28,9 %)). All patients had IHD combined with COPD, and had 
never exhibited the typical symptoms and/or signs of HF. Mean age was 60,0±10,01 
years. Patients were divided into groups according to GOLD 2017. In the control group 
were included 20 patients with IHD without COPD, relevant by age, sex and severity, 
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respectively the main group. Physical examination, 12-leads ECG, ambulatory 
ECG (Holter) monitoring, 6-WT, echocardiography, spyrometry, pulsoxymetry, Nt 
-proBNP level detection were performed to all patients
Results. All patients had stable angina: class II– 34 patients (75,6 %),class III – 
11 patients (24,4 %) according to the Canadian Cardiovascular Society. 32 patients had 
IHD assotieted with AH (71,1 %). Severity of COPD was assessed according to GOLD, 
2017: group B – 29 patients (64,4 %), group C – 10 (22,2 %), group D – 6 (13,4 %). 
Severity of airflow limitation was mild (FEV1 ≥80 % predicted) in 3 patients (6,7 %), 
moderate (50 %≤FEV1<80 % predicted) – 31 (68,9 %), severe (30 %≤FEV1<50 % 
predicted) – 11 (24,4 %)
We assessed LVEF for diagnosis of ALVD. 29 patients (64,4 %) had LVEF 
49–41 % (mid-range EF), 11(35,6 %) – 54–50 % (preserved EF). 12 (60,0 %) patients 
without COPD had LVEF 49–40 %, 8 (40,0 %) – less than 40 % (reduced EF).
Nt -proBNP level detection was performed. Mean level of Nt -proBNP in 
patients with IHD and COPD was 674,2±56,1 pg/ml. This is the so-called «gray zone». 
In patients without COPD ean level of Nt -proBNP was in within reference ranges.
We examined left ventrical geometry according to recommendations of 
European Association of Cardiovascular Imaging (EACVI) and the American 
Society of Echocardiography (ASE) 2015. Mean range of RWT was 0,44±0,129, LVM 
index – 79,3±13.76 g/m2, LVM – 139.5±24,48 g, LVV – 103,4±9,07 mL, LV volume 
index, 58,4±7,49 mL/m2. The value of the ejection fraction correlates with the type 
of remodeling of LV. EF≥50 % relevant concentric remodeling of LV. Concentric 
remedeling was also presented in 79,3 % cases EF 41–49 % (23 patients among 29). In 
patients without COPD, the eccentric type of remodeling predominated.
Conclusions. In patients with IHD combined with COPD, ALVD predominates 
with a preserved or mid-range EF, based on concentric LV remodeling. In our opinion, 
the definition of ALVD in such patients should include not only a reduced, but also 
mid-range and preserved EF, since this will determine the direction of treatment.
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In recent years, the role of the liver as one of the major organs of the immune 
system has been widely recognized due to the population of macrophages and killer 
cells it contains. They are components of the innate immune system. However, 
the immune response in case of non-alcoholic fatty liver disease (NAFLD) with 
concomitant obesity (OB) is insufficiently studied; in the literature there some data 
about changes in the liver innate immunity and the role of acquired immunity in the 
progression of NAFLD.
